Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LGN006
MIFTS: 52

Legionnaire Disease

Categories: Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Legionnaire Disease

About this section

MalaCards integrated aliases for Legionnaire Disease:

Name: Legionnaire Disease 56
Legionnaires' Disease 12 74 52 42 3 43 15 17 71
Legionnaires Disease 52 54 32
Legionella 12 15
Legionnaire Disease, Susceptibility to 56
Legionaire Disease, Susceptibility to 13
Infection by Legionella Pneumophilia 12
Legionnaire's Disease 12
Legionella Pneumonia 12
Legionellosis 52

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Infectious diseases
Anatomical: Respiratory diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10457
OMIM 56 608556
ICD9CM 34 482.84
MeSH 43 D007877
NCIt 49 C128339
SNOMED-CT 67 269574000
ICD10 32 A48.1
UMLS 71 C0023241
Sources

Summaries for Legionnaire Disease

About this section
NIH Rare Diseases : 52 Legionnaires' disease is a severe type of pneumonia caused by the bacteria Legionella . The species Legionella pneumophila causes most cases, but other species of Legionella can also cause the disease. It is named Legionnaires' disease because it was first discovered after a pneumonia outbreak among people who attended an American Legion Convention in Philadelphia, Pennsylvania in 1976. Most people exposed to Legionella do not become sick with Legionnaires' disease. People who do become sick usually develop symptoms within 2 to 10 days after exposure, but it may take longer. The first symptoms may include headache, chills, muscle pains, and a fever that can be 104?F (40?C) or higher. Additional symptoms usually develop 1 to 2 days after the first symptoms and may include coughing, shortness of breath, chest pain, diarrhea, nausea and vomiting, and confusion. While Legionnaires' disease mainly affects the lungs, it sometimes causes infections in other parts of the body, such as the heart or within body wounds. A person can become infected from Legionella when they inhale mist or water droplets that contain the bacteria. Sources of exposure may include showers, faucets, whirlpools, grocery store misters, and water droplets passing through ventilation systems in large buildings (such as hotels, office buildings, and hospitals). People who are more susceptible to developing Legionnaires' disease after an exposure include adults over age 50, current or former smokers, and people who have a weakened immune system or a chronic disease. Generally, neither the bacteria nor Legionnaires' disease is spread directly from person to person. While large exposures can result in outbreaks, the disease usually occurs in single, isolated cases. Legionnaires' disease may be suspected by symptoms. Pneumonia can be confirmed by a chest X-ray . Legionnaires' disease is diagnosed when one of the species of Legionella is found to be the cause of the pneumonia by testing a urine sample (urine culture ) or a sample of saliva and mucus that is coughed up (sputum culture ). Without treatment, the disease can be fatal. People with the disease who are otherwise healthy usually recover with antibiotics , although they may need to be cared for in a hospital. About 1 in 10 people with Legionnaires' disease will not survive due to complications such as respiratory failure, kidney failure, or septic shock. Of note, Legionella can also cause a milder illness called Pontiac fever , which causes flu-like symptoms, but does not cause pneumonia. Pontiac fever typically goes away without specific treatment.

MalaCards based summary : Legionnaire Disease, also known as legionnaires' disease, is related to legionellosis and pontiac fever, and has symptoms including fever, pruritus and snoring. An important gene associated with Legionnaire Disease is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Vesicle-mediated transport and Shigellosis. The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A legionellosis that is characterized by severe form of infection producing pneumonia. Symptoms include fever, chills, and cough.

OMIM : 56 Legionnaire disease (LD) is a type of pneumonia caused by Legionella pneumophila, a flagellated gram-negative bacterium found primarily in warm water environments. The disease and the bacterium were discovered following an outbreak traced to a 1976 American Legion convention in Philadelphia. A number of risk factors for acquiring LD have been identified, including age, smoking, chronic lung disease, cancer, and immunosuppression (summary by Hawn et al., 2003). (608556)

MedlinePlus : 42 Legionnaires' disease is a type of pneumonia caused by bacteria. You usually get it by breathing in mist from water that contains the bacteria. The mist may come from hot tubs, showers, or air-conditioning units for large buildings. The bacteria don't spread from person to person. Symptoms of Legionnaires' disease include high fever, chills, a cough, and sometimes muscle aches and headaches. Other types of pneumonia have similar symptoms. You will probably need a chest x-ray to diagnose the pneumonia. Lab tests can detect the specific bacteria that cause Legionnaires' disease. Most people exposed to the bacteria do not become sick. You are more likely to get sick if you Are older than 50 Smoke Have a chronic lung disease Have a weak immune system Legionnaires' disease is serious and can be life-threatening. However, most people recover with antibiotic treatment. Centers for Disease Control and Prevention

CDC : 3 Legionnaires' (LEE-juh-nares) disease is a serious type of pneumonia (lung infection) caused by Legionella (LEE-juh-nell-a) bacteria. People can get sick when they breathe in mist or accidently swallow water into the lungs containing Legionella.

Wikipedia : 74 Legionnaires' disease, also known as legionellosis, is a form of atypical pneumonia caused by any type... more...

Sources

Related Diseases for Legionnaire Disease

About this section

Diseases related to Legionnaire Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 484)
# Related Disease Score Top Affiliating Genes
1 legionellosis 33.4 TLR5 SEC22B RAB1B NLRC4 CD40LG CASP1
2 pontiac fever 31.9 SEC22B HPSE CD40LG ASPRV1
3 pneumonia 31.6 TLR5 PIK3C2A CRP CD40LG
4 chlamydia pneumonia 31.3 TLR5 CRP CD40LG
5 ornithosis 31.1 PIK3C2A CRP CD40LG
6 chlamydia 31.1 CRP CD40LG CASP1
7 pericardial effusion 31.0 PIK3C2A CRP CD40LG
8 exanthem 30.9 PIK3C2A CRP CD40LG
9 pericarditis 30.7 PIK3C2A CRP CD40LG
10 cardiogenic shock 30.7 PIK3C2A CRP
11 tularemia 30.7 NLRC4 CD40LG CASP1
12 leptospirosis 30.6 PIK3C2A CRP CD40LG
13 streptococcus pneumonia 30.6 TLR5 CRP CD40LG
14 viral exanthem 30.5 CRP CD40LG
15 acalculous cholecystitis 30.5 CRP CD40LG
16 bacteriuria 30.5 TLR5 CRP CD40LG
17 cat-scratch disease 30.5 CRP CD40LG
18 toxoplasmosis 30.5 TLR5 CD40LG CASP1
19 aspiration pneumonia 30.5 PIK3C2A CRP CD40LG
20 thrombocytopenia 30.3 TLR5 PIK3C2A HPSE CRP CD40LG
21 cryptogenic organizing pneumonia 30.3 NLRC4 CRP CD40LG
22 acute cystitis 30.3 TLR5 CRP CD40LG
23 bacterial infectious disease 30.3 TLR5 CRP CD40LG CASP1
24 typhoid fever 30.3 TLR5 CRP CD40LG CASP1
25 epidemic typhus 30.3 TLR5 CRP CD40LG
26 aortitis 30.2 CRP CD40LG
27 cervical adenitis 29.8 CRP CD40LG
28 acute kidney failure 10.6
29 lung mixed small cell and squamous cell carcinoma 10.6 PIK3C2A ASPRV1
30 ocular toxoplasmosis 10.6 TLR5 CD40LG
31 myringitis bullosa hemorrhagica 10.6 PIK3C2A CD40LG
32 sarcocystosis 10.6 PIK3C2A CD40LG
33 orbital plasma cell granuloma 10.6 PIK3C2A CRP
34 japanese spotted fever 10.6 CRP CD40LG
35 pyomyositis 10.6 PIK3C2A CRP
36 subdural empyema 10.6 CRP ASPRV1
37 rheumatic myocarditis 10.6 CRP ARF1
38 alkhurma hemorrhagic fever 10.6 PIK3C2A CD40LG
39 chronic orbital inflammation 10.5 CRP CD40LG
40 kidney disease 10.5
41 neuroretinitis 10.5 CRP CD40LG
42 splenic abscess 10.5 CRP CD40LG
43 ecthyma 10.5 CRP CD40LG
44 acute retinal necrosis syndrome 10.5 CD40LG ASPRV1
45 meningovascular neurosyphilis 10.5 CRP CD40LG
46 respiratory failure 10.5
47 tertiary syphilis 10.5 CRP CD40LG
48 optic papillitis 10.5 CRP CD40LG
49 opportunistic bacterial infectious disease 10.5 CRP CD40LG
50 gastrointestinal tuberculosis 10.5 CRP CD40LG

Graphical network of the top 20 diseases related to Legionnaire Disease:



Diseases related to Legionnaire Disease
Sources

Symptoms & Phenotypes for Legionnaire Disease

About this section

Clinical features from OMIM:

608556

UMLS symptoms related to Legionnaire Disease:


fever, pruritus, snoring, coughing

GenomeRNAi Phenotypes related to Legionnaire Disease according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.62 PIK3C2A
2 Decreased viability GR00055-A-2 9.62 PIK3C2A
3 Decreased viability GR00055-A-3 9.62 PIK3C2A
4 Decreased viability GR00221-A-1 9.62 PIK3C2A
5 Decreased viability GR00221-A-2 9.62 PIK3C2A
6 Decreased viability GR00221-A-4 9.62 PIK3C2A
7 Decreased viability GR00240-S-1 9.62 CD40LG PIK3C2A
8 Decreased viability GR00249-S 9.62 ANKLE1 CASP1 PIK3C2A
9 Decreased viability GR00342-S-1 9.62 PIK3C2A
10 Decreased viability GR00342-S-2 9.62 PIK3C2A
11 Decreased viability GR00342-S-3 9.62 PIK3C2A
12 Decreased viability GR00381-A-1 9.62 KRT18 RAB1B
13 Decreased viability GR00386-A-1 9.62 ARF1 CANX CASP1
14 Decreased viability GR00402-S-2 9.62 TBC1D5
Sources

Drugs & Therapeutics for Legionnaire Disease

About this section

Drugs for Legionnaire Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Azithromycin Approved Phase 4 83905-01-5 447043 55185
4
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7 Fluoroquinolones Phase 4
8 Cytochrome P-450 Enzyme Inhibitors Phase 4
9 Antitubercular Agents Phase 4
10 Erythromycin Estolate Phase 4
11 Erythromycin stearate Phase 4
12 Erythromycin Ethylsuccinate Phase 4
13 Antibodies Phase 4
14 Immunoglobulins Phase 4
15 Antineoplastic Agents, Hormonal Phase 4
16 Hormones Phase 4
17 Hormone Antagonists Phase 4
18 glucocorticoids Phase 4
19 Anti-Inflammatory Agents Phase 4
20
Ceftriaxone Approved Phase 3 73384-59-5 5361919 5479530
21
Ceftaroline fosamil Approved, Investigational Phase 3 229016-73-3
22 beta-Lactams Phase 3
23 Lactams Phase 3
24 Cytochrome P-450 CYP3A Inhibitors Phase 3
25
Moxifloxacin Approved, Investigational Phase 1 354812-41-2, 151096-09-2 152946
26
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
27
Rifampicin Approved Phase 1 13292-46-1 5381226 5458213
28
Streptomycin Approved, Vet_approved Phase 1 57-92-1 19649
29
Kanamycin Approved, Investigational, Vet_approved Phase 1 59-01-8, 8063-07-8 6032
30
Isoniazid Approved, Investigational Phase 1 54-85-3 3767
31
Pyrazinamide Approved, Investigational Phase 1 98-96-4 1046
32
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
33 Norgestimate, ethinyl estradiol drug combination Phase 1
34 Catalase Phase 1
35 Nicotinic Acids Phase 1
36 Lipid Regulating Agents Phase 1
37 Hypolipidemic Agents Phase 1
38 Vitamin B3 Phase 1
39 Antimetabolites Phase 1
40
Inosine pranobex Approved 36703-88-5
41
Diazepam Approved, Illicit, Investigational, Vet_approved 439-14-5 3016
42 Adjuvants, Immunologic
43 Antiviral Agents
44 Immunologic Factors
45 Anti-Bacterial Agents
46 Anti-Infective Agents
47 Antibiotics, Antitubercular

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Evaluation of a Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients Unknown status NCT02600806 Phase 4 Azithromycin;Levofloxacin
2 Costs and Effects of Early Switch of Intravenous to Oral Antibiotics in Severe Community-Acquired Pneumonia: a Multicenter Randomized Trial Completed NCT00273676 Phase 4
3 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
4 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Recruiting NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
5 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
6 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
7 A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia Completed NCT00111644 Phase 2 Ceftriaxone;beta-lactam;beta-lactam
8 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
9 Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection Unknown status NCT01646411
10 The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia Unknown status NCT02203110
11 Epidemiology of Community Acquired Pneumonia in North Israel Unknown status NCT00390819
12 Prospective Study on Benefits Derived From Microbiological Tests in Community-Acquired Pneumonia Unknown status NCT00312741
13 The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly: PneumOldCT Unknown status NCT02467192
14 Microbiology and Clinical Outcome of Community Acquired Pneumonia and Health-Care-Associated Pneumonia in Taiwan: a Multi-Center Study Unknown status NCT00873522
15 Plasma Protein Biomarker Based Diagnostics of Outcome in Sepsis & CAP Unknown status NCT00258869
16 The Impact of Legionella Urine Antigen Testing (LUAT) on the Local Epidemiology and Diagnosis of Legionella Pneumonia - A Hospital Based Study in Malaysia Completed NCT03200275
17 Molecular Epidemiology of Legionellosis in Grenoble Region Completed NCT02884700
18 Zithromac Iv Special Investigation For Legionella Infection. Completed NCT01784770 Azithromycin IV
19 Prevalence of Legionella Infections, Bacterial Etiology in Pneumonia Among Patients Admitted to Hospital,- and Risk Factors/Characteristics for These Patients.(Translated From Norwegian) Completed NCT00467701
20 Pulmonary Complications of HIV Infection Study (PACS) Completed NCT00005273
21 A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy Completed NCT00002297 Inosine pranobex
22 Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in the Empiric Treatment of Community-Acquired Pneumonia Completed NCT01983839
23 Etiology of Community Acquired Pneumonia Completed NCT00471757
24 Detection of Microorganisms and Antibiotic Resistance Genes in Lower Respiratory Tract (LRT) Samples Using the Curetis Unyvero LRT55 Application Completed NCT01922024
25 Identification of Bacterial Species and Their Antibiotic-Resistant Spectrum in Sputum Specimen From the Patients With Pneumonia Via Nuclear Acid Detection Assay Completed NCT00567827
26 A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates Completed NCT01328873
27 Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR Completed NCT00275691
28 Infectious Etiology of Acute Exacerbations of COPD in Hong Kong Completed NCT00441389
29 Procalcitonin Antibiotic Consensus Trial (ProACT) Completed NCT02130986
30 Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests (RDTs), Biomarkers, and Standard of Care Procedures (SoCs) for the Etiology Diagnoses of Pneumonia in Pediatric Patients to Improve Clinical Management in Indonesia. Completed NCT03366454
31 Prevalence of Sleep Apnea-hypopnea Syndrome in Patients With Community Acquired Pneumonia, Prospective and Comparative Case-control Study Completed NCT01071421
32 Proposed Procalcitonin Re-Implementation Protocol for Johns Hopkins Bayview Medical Center (JHBMC): A Stewardship Project Completed NCT03109106
33 Randomized Controlled Trial of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit Completed NCT02056119
34 Accuracy of Routine Biomarkers and Blood Leucocytes Count to Assist Diagnosis of COVID-19-related Pneumonia in Adult Patients Visiting the Emergency Department Completed NCT04401241
35 Nosocomial and Community Acquired Legionella Pneumophila Pneumonia, a Retrospective Case Series Recruiting NCT04106037
36 Bacterial and Human Biomarkers of Prognostic Value for Severe Legionnaire's Disease Recruiting NCT03064737
37 Impact of Comprehensive Molecular Tests on Antimicrobial Stewardship in Community-acquired Pneumonia: an Open, Controlled and Randomized Clinical Trial Recruiting NCT04158492
38 Impact of a Strategy Combining the Rapid Polymerase Chain Reaction Platform FilmArray® and the Intervention of an Antimicrobial Stewardship Team in Hospital-acquired Pneumonia in Non-mechanically Ventilated Patients: a Randomized Controlled Trial. Recruiting NCT04153682
39 Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial Recruiting NCT04334850
40 Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR Recruiting NCT04346056
41 Legionella Pneumonia's Effect on Olfactory Function Suspended NCT03321786
42 Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis Terminated NCT00452153

Search NIH Clinical Center for Legionnaire Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ERYTHROMYCIN PWDR

Cochrane evidence based reviews: legionnaires' disease

Sources

Genetic Tests for Legionnaire Disease

About this section
Sources

Anatomical Context for Legionnaire Disease

About this section

MalaCards organs/tissues related to Legionnaire Disease:

40
Lung, Testes, Heart, Kidney, Monocytes, Colon, Bone
Sources

Publications for Legionnaire Disease

About this section

Articles related to Legionnaire Disease:

(show top 50) (show all 2926)
# Title Authors PMID Year
1
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. 56 6 61 54
14623910 2003
2
Residential water heater cleaning and occurrence of Legionella in Flint, MI. 42 61
31940510 2020
3
Legionnaires' Disease Cases at a Large Community Hospital-Common and Underdiagnosed. 61 42
31947755 2020
4
Impaired TLR5 functionality is associated with survival in melioidosis. 6
23447684 2013
5
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. 6
16027372 2005
6
Managing and preventing Legionella infections. 42
32068708 2020
7
Legionella community-acquired pneumonia (CAP) presenting with spontaneous bilateral pneumothoraces. 54 61
18482636 2008
8
Host susceptibility and clinical outcomes in toll-like receptor 5-deficient patients with typhoid fever in Vietnam. 61 54
15747241 2005
9
Transmission of Legionnaires' Disease through Toilet Flushing. 61
32568063 2020
10
The structure of the Legionella response regulator LqsR reveals amino acids critical for phosphorylation and dimerization. 61
31997467 2020
11
Identification of two aptamers binding to Legionella pneumophila with high affinity and specificity. 61
32499557 2020
12
Mitigation of Expression of Virulence Genes in Legionella pneumophila Internalized in the Free-Living Amoeba Willaertia magna C2c Maky. 61
32517040 2020
13
Legionella effector AnkX displaces the switch II region for Rab1b phosphocholination. 61
32440549 2020
14
The draft genome of Staphylococcus warneri TRPF4, a bacteriocin producer with potent activity against the causative agent of Legionnaires' Disease. 61
32399382 2020
15
Large community-acquired Legionnaires' disease outbreak caused by Legionella pneumophila serogroup 1, Italy, July to August 2018. 61
32458793 2020
16
Persistent Legionnaires' Disease and Associated Antibiotic Treatment Engender a Highly Disturbed Pulmonary Microbiome Enriched in Opportunistic Microorganisms. 61
32430469 2020
17
Green waste compost as potential reservoirs of Legionella in the Netherlands. 61
32470567 2020
18
Structure and functional analysis of the Legionella pneumophila chitinase ChiA reveals a novel mechanism of metal-dependent mucin degradation. 61
32365117 2020
19
Population-Based Assessment of Clinical Risk Factors for Legionnaires' Disease. 61
31617567 2020
20
Invasive pulmonary aspergillosis in an ICU patient with Legionnaires' disease: A diagnostic challenge. 61
32418638 2020
21
Legionnaires' Disease in Pediatric Patients, Control Measures and 5-Year Follow-Up. 61
32472821 2020
22
What is the risk of missing legionellosis relying on urinary antigen testing solely? A retrospective Belgian multicenter study. 61
31838606 2020
23
Legionella pneumophila and Protozoan Hosts: Implications for the Control of Hospital and Potable Water Systems. 61
32326561 2020
24
The Legionella pneumophila Metaeffector Lpg2505 (MesI) Regulates SidI-Mediated Translation Inhibition and Novel Glycosyl Hydrolase Activity. 61
32122942 2020
25
High-polyphenol extracts from Sorghum bicolor attenuate replication of Legionella pneumophila within RAW 264.7 macrophages. 61
32188994 2020
26
Legionella pneumophila occurrence in drinking water supplied by private wells. 61
31904109 2020
27
Impact of temperature on Legionella pneumophila, its protozoan host cells, and the microbial diversity of the biofilm community of a pilot cooling tower. 61
31931228 2020
28
A real-time PCR for specific detection of the Legionella pneumophila serogroup 1 ST1 complex. 61
31525518 2020
29
Short-term associations between legionnaires' disease incidence and meteorological variables in Belgium, 2011-2019. 61
32345387 2020
30
Comparison of Legionella K-set® and BinaxNOW® Legionella for diagnosing Legionnaires' disease on concentrated urine samples. 61
32303927 2020
31
Differential Seasonality of Legionnaires' Disease by Exposure Category. 61
32353925 2020
32
Fatal Fulminant Legionnaires' Disease in a Patient on Maintenance Hemodialysis. 61
32321897 2020
33
Slowly or Nonresolving Legionnaires' Disease: Case Series and Literature Review. 61
31242293 2020
34
Legionnaires Disease Death Linked to Home Water Contamination. 61
32286650 2020
35
Divergent Evolution of Legionella RCC1 Repeat Effectors Defines the Range of Ran GTPase Cycle Targets. 61
32209684 2020
36
Serotyping and detection of pathogenecity loci of environmental isolates of Legionella pneumophila using MALDI-TOF MS. 61
31978736 2020
37
Legionella risk in evaporative cooling systems and underlying causes of associated breaches in health and safety compliance. 61
31978741 2020
38
Cerebellar ataxia a unique initial presentation of Legionnaires' disease. 61
32161074 2020
39
Applying probability-weighted incubation period distributions to traditional wind rose methodology to improve public health investigations of Legionnaires' disease outbreaks. 61
32070446 2020
40
Point-of-use filters for prevention of health care-acquired Legionnaires' disease: Field evaluation of a new filter product and literature review. 61
31668765 2020
41
The bacterial deubiquitinase Ceg23 regulates the association of Lys-63-linked polyubiquitin molecules on the Legionella phagosome. 61
31907282 2020
42
Molecular detection of opportunistic premise plumbing pathogens in rural Louisiana's drinking water distribution system. 61
31740037 2020
43
Presence of Legionella spp. in cooling towers: the role of microbial diversity, Pseudomonas, and continuous chlorine application. 61
31726393 2020
44
[Legionnaires' disease with pronounced cerebellar involvement: case report and literature review]. 61
32062882 2020
45
Inhaled Epoprostenol to Facilitate Safe Transport in Legionnaires' Disease. 61
31915089 2020
46
Asymptomatic cardiac and gallbladder involvement at initial presentation of Legionnaires' disease. 61
32218409 2020
47
A pseudo-outbreak of Legionnaires' disease in an acute-care hospital. 61
31896386 2020
48
Fatal Case of Legionnaires' Disease After Home Exposure to Legionella pneumophila Serogroup 3 - Wisconsin, 2018. 61
32106217 2020
49
Complete Genome Sequence of a Legionella longbeachae Serogroup 2 Isolate Derived from a Patient with Legionnaires' Disease. 61
32001572 2020
50
Phosphoinositides and the Fate of Legionella in Phagocytes. 61
32117224 2020
Sources

Variations for Legionnaire Disease

About this section

ClinVar genetic disease variations for Legionnaire Disease:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TLR5 NM_003268.6(TLR5):c.1174C>T (p.Arg392Ter)SNV protective,risk factor 6658 rs5744168 1:223285200-223285200 1:223111858-223111858
2 TLR5 NM_003268.6(TLR5):c.1775A>G (p.Asn592Ser)SNV risk factor 6659 rs2072493 1:223284599-223284599 1:223111257-223111257
Sources

Expression for Legionnaire Disease

About this section
Search GEO for disease gene expression data for Legionnaire Disease.
Sources

Pathways for Legionnaire Disease

About this section

Pathways related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Vesicle-mediated transport 65
Show member pathways
 12.86 SEC22B RAB5A RAB35 RAB1B PIK3C2A OCRL
2
Shigellosis 36
12.05 TLR5 NLRC4 CASP1 ARF1
3
PI Metabolism 65
Show member pathways
 11.82 RAB5A PIK3C2A OCRL ARF1
4
Salmonella infection (KEGG) 36
11.67 TLR5 RAB5A NLRC4 CASP1 ARF1
5
RAB GEFs exchange GTP for GDP on RABs 65
11.53 RAB5A RAB35 RAB1B
6
RAB geranylgeranylation 65
11.31 RAB5A RAB35 RAB1B
7
Legionellosis 36
10.86 TLR5 SEC22B RAB1B NLRC4 CASP1 ARF1
Sources

GO Terms for Legionnaire Disease

About this section

Cellular components related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.89 USH2A TLR5 TBC1D5 SEC22B RAB5A RAB35
2 endomembrane system GO:0012505 9.56 RAB5A RAB35 RAB1B ARF1
3 phagocytic vesicle membrane GO:0030670 9.54 SEC22B RAB5A OCRL
4 clathrin-coated vesicle GO:0030136 9.5 RAB35 PIK3C2A OCRL
5 COPI-coated vesicle GO:0030137 9.43 SEC22B ARF1
6 anchored component of synaptic vesicle membrane GO:0098993 9.4 RAB5A RAB35
7 IPAF inflammasome complex GO:0072557 9.16 NLRC4 CASP1
8 melanosome GO:0042470 8.92 SEC22B RAB5A RAB35 CANX

Biological processes related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular protein transport GO:0006886 9.55 TBC1D5 RAB5A RAB35 RAB1B ARF1
2 protein transport GO:0015031 9.5 TBC1D5 SEC22B RAB5A RAB35 RAB1B ARF1
3 Rab protein signal transduction GO:0032482 9.43 RAB5A RAB35 RAB1B
4 regulation of autophagosome assembly GO:2000785 9.32 RAB5A RAB1B
5 phosphatidylinositol biosynthetic process GO:0006661 8.92 RAB5A PIK3C2A OCRL ARF1

Molecular functions related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 USH2A TLR5 TBC1D5 SEC22B RAB5A RAB35
2 GDP binding GO:0019003 9.13 RAB5A RAB35 ARF1
Sources

Sources for Legionnaire Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....